Chaty number. 1181623 BRITISH SOCIETh OF ENDOVASCULAR THERAPY UNAUDITED TRUSTEES. REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2026 Armstrongwatson. Accoufttants, Business & Financial Advisers
BRITISH SOCIEfY OF ENOOVASCULAR THERAPY CONTENTS Page Reference and adminis¢rative detsils of the Charity. its Trustèes and advisers Trustees, report Independent examinerfs report Statsrnent of financial activities Balance sh•et Notes to the financial statements 9-16
BRITISH SOCIEfY OF ENDOVASCULAR THERAPY REFERENCE AND ADMINISTRATIVE DEfAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 JANUARY Z026 Tru5tses Professor B Modarai. Truslee Iresigned 27 June 20251 Mr S Neequaye. Trustee Mr P Bews. Trustee Mr P Moxey, Trustee Mr D Bosanquet. Trusiee DT R Morgan. Trustee lappoinled 27 June 20251 K4s E Wilton. Trustee Mr M Claridge. Tru51ee Ms B Sandford. Totee Iresigned 27 June 20251 Dr K Lewts. Trustee Iresigned 27 June 202SI Dr S Dindyal. Trusteè Dr A Wigham. Truslee Mr N Dattani. Tiustee Miss K Sritharan. Trusl*S MT A Patel. Tru51ee Mr S Nandhra. Trusiee Mi J Mccaslin. Trustee Mr M Juszczak. TFUStee lappow)teO 27 June 20251 Mr 8 Vijwagar. Tnjstee Izpwnted 27 Jttne 202$) Charity registgred numb¢r 1181623 Accountants Armstrong Wat50n LLP Carleton House 136 Gray Street Worktngton Curnbria CA14 1LP ac
BRITISH SOCIEfY OF ENDOVASCULAR THEPAPY TRUSTEES. REPORT FOR THE YEAR ENDED 31 JANUARY 2026 The Trustees present their annual port tcgelher wrth the financial Statements of the Charily for the 1 Febwary 2025 to 31 January 2026. Objectives and activiknes a. Poll¢ies and objectives The Bri115h Souety of Endova5cu13r Therapy $ primary role is lo promole the besl in research. Iraiiii119. lutslit)11 and clinical piactice for the benefit of people with mediL31 condrtions who Uld potentially be helped by endova5cular therapies. 11 achieves this with the loong aims". 11 to advance heallh by promoiing saentific researth. education and training in endoYdsrAJlar trealrnenl and procedures", and 21 to advance the edurabon of the public and parlxlarty amongst heatth professiona15 in endovascular trealment and pr[teduS The Society continues ils cornrnilrnenl to Improvtng the quality ol enLlova5DJlaf surgery in the UK through ils training courses. Annual Meeting. and Training ancl Research Fellow5hip5. The BSET rneeting is the onfy ded5caied UK meeting fof Ihe presentslion of endovascular fyseareh. 11$ unique format encourages hig level discussion and partiopation and the meeting faculty attracts the wortd's leading endovascular specialists. The Society's Iruslees have complied with Ihe duty in Section 4 of the Chanties Act 2011 to have due regard 10 Public Benefft guidance published by the Charity Commission. Achievements and perfornianc a. Education and Training The Society s Annual Meeting was held In June 2025. The meeiing attraded over 120 endovascular consultants. trainees and allied medical piofes510nals. The programme ¢offlpri5ed presentations from guest speakers from the USA. Italy, and thè Nethert3nds. th aostract and poster presenlalions from endova5¢ular trainees in the UK. The Souety award5 a prize for the besi Pfesenled abstrèct in ihe Aortic Prize Session and Peripheral PrEe Session. as well as for the best posier presentation at the Annual Meeting. A National Vascular Tr31ning Day was hekt pnor lo the Annual Meeiing for 36 junior endovascular trainees comprisirig srnall case based ¢fiscussI< groups and prac111 hands-¢n training on endovas¢ular dewces. The BSET Endovascular Training Course iyas herd in March 2025 for vascular and interv2nlional radiDlogy trasnees. Attendees were taughl in small group sessions lo¢YLin9 al the finer points of endovascular treatment alongside Jndustry who prod hands-oA praclical training on surgical dewces. The BSET Training Courses and Annual Meeiing are wdl reVe4 by attendees. particulady endova5cular trainees. Feedback received Irom the Annual Meeting Indudes cA)mments that the programme mnlenl was of a high 51andard." that the meeting Provides an excellent opportunlty to get up to date practice Inlortnalion and new guidelilles.. and that rf allows indiwduals to focus on ongoing research and training for the benefit of patnIs. Attendees al the Society Training Courses found Ihal they were wem slru¢ture(I wrth opportunilies for peer discussion offering the greatesl leaming value. In particular attendees found that the f3culty's expertise and the presentations were of Ihe highest standard. oflenng insightful and welksttyctured content that was dinically relevant. The BSET Fellowship Programme was ao*ertised for 2025 and one Endovascular Training Fellowship ivas appointed who will undertake a six month training posl at Manthesler Univefslty Hospital. The Training Fellowship provides an opportunity for vascAJlar or intefftnlional radio109y trainee5 to acquire new or more omplex end0Vas¢ur skills. Page 2
8RmSH SOCIETY OF ENDOVASCULAR THERAPY TRUSTEES. REPORT ICONnNUEDI FOR THE YEAR ENDED 31 JANUARY 2026 A¢hievements and perfonnance Icontinuedl vascular Travel Fellows were appointed. and funding was given to support lurther train1ng in specialist .'4%SCJlar unrts in Australia and Sweden. ellovis prov5de a wntten report of their Fellowship experience which is made available on the Society's -S"c 2nd also attend the Annual Meeting lo give a PSentation lo attendees. b. R¢sear¢h '.s committed to dvill9 excellene* in Search and improving oulcome5 for patients by raising the profile èfLI irnpath of endovascular research. 3SET Pump-Priming Grant Award was established to support indiviLluals wsth strong Te5ear¢h Ideas and a genoine enthus13Stn for a speufi¢ project. but who may require a relatelY modest amount of funtling lo tum Ineir idea5 Into realty. Major research gratits are often aimed at larye-scale projects. whith can be difficult for early-career researcher5 to access. The Pums>Priming Grant aims lo bridge this gap by providing funding for preliminary data collection. feasibility studies. or specffic components of a larger research programme. These funds nelp reapienls gather Ihe necessary evidence and mornentum needed lo secure more 5ub51anlial funding Ir. the future. Two Research Pump Priming Grants were warded in 2025 to support research proiecis in the field of endovascular Iherapy. The Tesearch projec15 awarded were the BEACON Study - 8eetrooi Evaluation and Acceptability on Clinical Outcomes sn lower limb endovascular intervention.. and Personalised Prediclioi of Resten0515 Risk Through Integrated IVUS-Based Compulational Flow Dynami¢5 and Microfluidic Flow Svslem Experimentation. The awardees ¥MII present the outcomes of their searCh al a future Annual Meeting. The GLO8ALSTAR (Global Collaborators on Advanced Stenl-Graft Techniques for Aneurysrn Repair) reg".s.:ry an Industry-supported research initiative. was lavnched th Ihe aim of c3Ptuiing comprehensive aata or. complex endova5cular aneurysm repairs. The registry reported its inrtial results back In 2012, and Sin thep, ,1 has significantly expanded its Scopè. GLOBALSTAR now indudes data from over 1.000 complex abdotylnal aortic aneurysm IAAAI repairs. with follow-up dala extending up lo 10 years. This long-term data Is InvalaDIe 'o' assessing the efficacy and durability of adVand stent-graft iechniques in the managtsment of COTDlex aneurysms. The project has benefited frorn patient involvernenvfeedback through the Sl George $ Vasc.. lar patient adwsory group. The manusuipt wa5 published in the British Journal of Surgery. It Is hoped that publication of the final dala wll wsrtivety in1luen comrni5s¥)ning decisions w¢thin the NHS. ¢. Collaborative work Dis¢ussions contlFiue with the British Soriety of Inlervenlional Radiology wilh the aim to form a c105er relationship betsveen Ihe S¢xieties. In the pa51 year. mutual engagement at BSIR and BSET CD.p.cil meeting5, and presence at respective annual meetings has been wel received, ctslminaling in the 8SIR meets BSET 'session at the BSIR Annual Scientific meeJThg in Liverpool in November 2025. This cr05s-pollinatioD of people and ideas enriche$ the experience ol our members and reinlorces the Societies commitmep.t to continuous leaning. The Trustees worked with the charty The Circutation Foundab"on io assisl an update on their patient infomation leaflet5 relating to endovascular treatment. d. Structure. govemanee and mana9ement '. istee Theeling5 were held in person and two wjine during this period. Organisalional matters were dealt 'ee ryEw ru5tees were eleded in June 2025 Page 3
BRITtSH SOCIEfY OF ENCQVASCULAR YHERAPY TRUSTEES, REPORT ICONMNUEDI FOR THE YEAR ENDED 31 JANUARY 2026 Achievements and perfornian¢& Icontinuedl e. rn5 and key obje¢tives for fu¢ur• pfrriods The Trustees plan lo continue lo hokt Ihe Endovèscular Training Course in MaF¢h 2026 and Nalional Vascular Training Day in June 2026 for vascuLar and IR Irainees. The 2026 Annual meetr.ng be thc 20th anniversary of the Soriety and the TnJ8tees aged 10 publish docurnenl oulinJng the achievemenls of the Soaety during this period. An En(Ji)v35cular Training Fellowship and Travel Fdknw5hwlsl wll be offered in 2026. Two Research Purnp Priming Gfants 11 be wlarded lo supwt research projects in the field of endovascular therapy. Discussions will continue with the 8rit15h Soaety of Inlervenlional Radiology wrth the aim lo estsblish a Joini educational webinar for BST and BSIR trainees. The Trustees will rewew its polrc4e5. induding the eslabh'shmeni ol a sk register. Consideration would be given lo retrtewing the industry sporbsorship levels to ensure the meeting programme was balanced ané allow greatef exwsure of industry produci$ to trainee5. Financial vieW a. Reserves policy It was agreed lo increase the level of reserves lo ¢Jth)K to cover fv40 years, operab.ng costs Tn the light of increasing costs. This wll allow BSET lo keep appfoximately 2 year5 annual operaiing costs In reserve. The Trustees bwll continue lo asse5S the level of seNe5 It requires and wll update Ihe wlicy rf it 15 felt its frnancTal quirements have changed. The fvnds of £104.OQO had been reinvested into the Shawbfook 12 month fixed rate saver a¢wurt with an interest of 4.8%. and it was agreed lo add up 10 a further £100K into this account. Consideration would be given to investing the reSee fvnds iftlo a charitable investment portfolio. The feseryes polity ensures Untred funos are 5uffiueni to mee¢ years. aCtlty ofthe Soctety, 10 cover. al The risk of unforeseen emergency or othef unexpeded need for fvnd$. e.g. to provide '$eed-funding' for an urgent project. bl Unforeseen day-l¢pday operational costs, e.g. ernplowng temporary staff to cover a long-tertn sick absence. cl A source af income. &.g. a swn50rship of our meetings. not being renewed. Funds rnighl be needed to gwe the trustees time lo take action if income falls below eXClat10n$. dl The need to fund short-temi deficrts In a ush bud9el. e.g. money rnay rÈeed lo be Spent before a frJnding grant is received. age4
BRITESH SOCIEfY OF ENDOVAS¢ULAR THERAPY TRUSTEES. REPORT ICONTrNUEDI FOR THE YEAR ENDED 31 JANUARY 2026 StNcture. govemance and management a. Methods of appointment or glectlon of TTUStees '.rustee 15 appointed for a term ol three years. In seleclsng indmduals for appoinlrnent, the Charity Iwsiees _s.. have regard lo Ihe skills, knowledge and experience neeOeL1 for the effective adm¢ni51ration of the CIO. -e last meeting, Council fell that the scoring pro$$ for electing new members should be reviewed and that spculo be more transparent lo those who were standing for eleaion as to the requiTernenls lor serving on unG,l. From 2026, indlwduals would be reouested to ()pte an awitstion fomi oudining their rtdovascular experience to date Alignment ol endovascular experien in relatioTh to BSET aaiwbes in aspects of patiènt care, service organ15ation, research ané leaching Endovascular training experience Quality of personal slaternenl Commitment lo BSET All new trustees are asked to sign a statement of e9ibI1ty and a sent the folsowng.. The charitrfs constitution The minutes of Council meetings for the prewous year. L15t of currènt Imslees an¢J conlact details.. Annual list ol dales of trustee meeling$'. The m051 iecent Charity accounts.. A copy ofthe Chanty Commission publt(ation'The Essenb"al TnJslee- What you need lo know.. There are four trustee Icounrill meetings a year at which operational and finanoal rnatters of the Society are discussed. and Stratègic decisions about the diredion of thè chanty are tsken. In bee8 meetings, decisions are made by telephone or e-mail communication ben Ihe Honorary Officers and other trustees. An administrator working tsn a consultsncy basis deals with matters pertaining to the general tsryanisaiiop o,. ;; Society. Annual Meeting and other events. BSET ha5 collaborative links wrth the Royal College of Surgeons IEngl. Royal College of Surgeon5 (Ed,, Ifascular Society of Great 8ritain and Iland. the Rouleaux Club. the British Society ol Inlerveniion81 Racioloay *he BSIR Trainees to help lurlher Ihe aons of the de¥ehTing $peoty and ¢0 delNef hiyh stsndaT4s o., practi. ¢rroved by order of the members of the boasd of Trustees and 51gned on their behalf by.. Mf J Mccaslin Mr P Bevi$
BRITISH SOCIETY OF ENDOVASCULAR THERAPY INDEPENDENT EXAMINER'S REPORT FOR THE YEAR END£D 31 JANUARY 2026 Independent examinerfs pOrtt0 th• Trustees of 8iib$h So¢lety ot Endovascular Therapy I'the Charity'l I report to the charity Trustees on my examinab.on of the accounts of the Chanty lor the year endod 31 January 2026. Re$ponsibilTrties and basis of report A5 the Trustees of the ChaTrty you arè responsible for the pparatIon of the accounls in accordan wrth the uirernen15 of Ihe Charities Act 2011 (Ihe 2011 Act'l. I report in respe of my exam¢rhation of the Chariws accounts Gqrried out Under seaion 145 01 the 2011 Act and in carrwng out my examination I have followed the appficable Directions gwen by the Charity Comrnission undèr Section 14515llbl of the 2011 Act. Independent examinerfs stat¢mnt Your attention is drawn lo the fact that the Charity has prepared the accounts ift accordance with Accounting and Reporting by Charities.. Siatement of Recommended Praciice applicable to chafrties prepanng their accounts in accordance with the Financial Reporting Standard applicable in the UK al Republic of Irelanc5 IFRS 1021 In preference 10 Ihè Accounting and Reporting by Chanties Slaiemeni of Recommended Practice issued on 1 Apfil 2005 which is ieferred lo in the exlant iegulalions bul has beèn wilhdiawn. l understand that this has been done in order fo¥ Ihe accounls to prowde a true and lair wew in alrdance with the Generally Accepled Accounting Pra¢ltce eNecbve for reportin9 pericxjs beginning on or afler l January 2015. I have colnpleted my examinab"on. I confirn that no matters have corne to my atlention in connethon with the examination giving me cause lo belve that in any material re5peci" ac¢ounting records were nol kept in $peth olthe Charity as QUIred by 5ectton 130 01 the 2011 Act.. or the accounts do not accord wilh those records." or the accounts do not rANnply wilh the applicable requ1MentS concerning the lonn and content of accounls set out In the Charities IAccounls and Reports) Regulations 2008 other than any requirement that the accounts g(ve a 'iwe and faiF' which is nol a matt&r Considered as part of an independenl examination. I have no concerns and have come across no other matters in connefflion wth the examination 10 which attention should be drawn in this report in order Its enable a proper understanding of the accounts lo reached. Signed.. Dated". Io.Ll.IC. Steven Kirkbridè BFP FCA ATT MMT Armstrong Watson LLP. Woth"ngton Paae 8
BRITISH SOCIETY OF ENDOVASCULAR THERAPY STATEMENT OF FINANCIAL ACTfviTIES FOR THE YEAR ENDED 31 JANUARY 2026 Unft$tri¢ttd funds 2026 Restrictsd fund$ 2026 Totsl funds Z026 rotal luiids 2025 Note Income from.. Donations and legac4es Other trading activities Investments Other income 34.175 34.175 308.997 4.377 16,462 35,988 166,571 956 30.998 308.997 4,377 16.462 Total income 329,836 34.175 364,011 234.513 Expèndlture on: charitab aclmtiès 301.950 301.950 765.326 rotal expenditu 301.950 301.950 165.326 Net income Transfers beleen hjnds 27.886 34.175 34.175 134.1751 62,061 69 187 Net movement in funds 62.061 62.061 69 787 Reconciliation of funds: Total funds broughl forward Nel movement in funds 508,718 62,061 S08.718 62,061 439.531 69 787 Total lund5 carried fonrdrd 570,779 $70.779 508 718 The Statement of finanual activities indudes all g8in5 and 105se5 recognised in the year. The notes on pages 9 10 16 fomi part olthese finanual slalements. Jage
8RmsH SOCIETY OF ENDOVASCULAR THERAPY BALANCE SHEET AS AT 31 JANUARY 2026 2026 2025 Note Fixed assets Cunont assets Detytors Cash at bank and in hand 81.360 501.523 SlQ.398 $82.883 510,398 Current Ilabilitiès Creditors. amounts fdling due within one year 10 112.1041 fl.680} Net current assets S70.779 508.778 Total assets less current liabilitt•S 570.779 508, 718 Net asset¥ excluding pension a$$et S70.779 508. 718 Total net assets $70.779 508.778 Charity funds Restricted funds UnStriCted fLtnds 570,779 508. 778 Total funds 570,779 508. 778 The finallal statements were appFoved and 8hOnSed for issue by the Trustees and signed oft Iheir behalf by.. Mr J McCa$lin Mr P Bevis Dale.. ILb- c è The notes on pages 9 10 16 fomi pam ol these financial 5talements_ age8
BRrrisH SOCIETY OF ENDOVASCULAR THERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE Y&4R ENDEO 31 JANUARY 2026 General Infomation Britrsh Socièty of Endovascutar Therapy is a charilabje ¥)fxJrporated organisation. Accounling policits 2.1 Basis of preparntlon of financlal statements The financial slalements have been prepa in accordance iyith the Charities SORP IFRS 1021- Accounting and Repong by Charities" Siatemenl of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable In the UK an¢J Republic of I13nd IFRS 1021 (effective 1 January 20191. the Finan(xal Reporiing Standard applicable in the UK and Republic of Ireland IFRS 1021 and the Charities Ad 2011. The fiTtantyal $13ttment$ have been prepared to gNe 8 'true and lairf view and have departed from the Charities (Accounts and Reports) ReguEation$ 2008 to the extent required to provide a Lrue and fairf view. This departure has inVoe folh)wing the Chanbes SORP IFRS 1021 publisned '.n October 2019 ralher than the Accounting and Reporting by Charities.. Statement of Recommended Prad5cè èlledive from 1 Apnl 2005 which has stnrR been thdraWn. Bntish Society of Endovascuiar Thefapy meets the definElion of a public benefit entity under FRS ' 02. Assets and liabilities are initially recogniseij at histortsl Cost or transaction value unless otnen'iise statecl in the relevant accounting policy. 2.2 Golng eoncem Al the time of approwng Ihe financial statements. Ihè truslees have a reasonable expectation T8[ t charity has adequate resources to conb.nue In operational estenCe for the foreseeatyle future. the Injslees continue 10 adopt the going concem basis of 3ccounting in preparifig the f staternents. 2.3 Income All income Is fecnISed or*ce the Chanty has enlrtlemeni lo the income. It Is probable ="a'. iTrcom8 will be received and the amounl of inrx)me revable can be measured Teli3bly. Other income is cOgnised in the period in whth it is reable 3nd to the extent the goo-5 been prowded or on completion ol the seTrice. 2.4 Expenditure Expenditure is reCOglsed On the is a legal or construdive obfjgation lo tfansfer econow.c - lo a third party. it Is probable that a transfer of economie benefits be required In seL. the amount ol the obligation can be measured reliably. Expendrture is dassified by ae4IV')' of each acliwty are made up of the toial of ¢liwl costs and shad costs Indudina s. involved in undertaking each actmty. DiTeci costs attribulable to a single activity are allcca:.&c lo that activity. Shared cost5 whith contribute to more Ihaft one actilty and 5UPPOrt. -OSiS not attributable lo a single actsvity are apportioned between those activities on a basis co-. s 5'.e- the use of resources. Central staff costs are allaled on the basis ol time 5peni. anc de-""- tharges alkncated on the portion ol the as5èfs use. $15 Expenditure on Charitable actiwlies Is Inujrred on direcUy undertaking the acbvities %¥hic Chanvs obseaives. as well as any as50cEaied support costs. All expenditu 1$ inclusive of irrecoverablp VAT.
8RfnsH SOCIETY OF ENOOVASCULAR THERAPY NOTES TO ThE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2026 A¢¢ountln9 polici¢s Icontinuedl 2.S Taxation The Charlty is consjdered to pass the te51s set out in Paragraph 1 Schedule 8 of the Finanr£ Act 2010 and therefore it meets the definition of 3 tharilable company for UK corporation tax purposes. Accordingly. the Charty is potential exempl from taxation ift respecl of income Dr capital gains received within ¢alegories covered by Chapier 3 Part 11 of the Coworation Tax kn 2010 or Section 256 of the Taxalion of Chargeable Gain$ Act 1992. to the extent that such income or gains afe applied exdusivety to chariiabje wrpose5. 2.6 Debtors Trade and olber debtors are recognised at the setuement arnounl after any trade discount offered. PpaymentS are valued at the amount prepaid net of any trade discounis due. 2.7 Cash at bank and in hand Cash at bank and In hand indtsdes cash and shon-lerm highty h.qwd investtnenls wrth a short maturity of three months or less from the éaie of 3cquisilTon or opening of the depDsII ¢Y sirnilar a¢couni. 2.8 Lbabilities and provisions Liabilrties are regnISed when Ihere is an ¢)bl)ats0n at thè Baknce sheet date as 8 sU11 of a past event. il is probable that a transfer ol ecoftornie nefit will be required in settlement, and the amount ol ltte sememenl can be estimated reliably. Liakn'lits are recognised at the amount thai the Chanty anliupales it wll pay to settle the debt or the amount il has reied as advanced panentS for the gools or services il must provide. Prowsions a measured at the best estimate of the amounts required lo sellle the obligation. Where the effeel of the time value ol money is material. the prowsion is based on the present value of those arnounls. discounted al Ihe pr&lax discount rale that refiecls the risks speufic lo the liability. The unwsnding of Ihe discouni is recognised in the Stateffieni of finanual athiviiies as a finance cost. 2.9 Financial instruments The Charity has finanual assets and finanoal liabilrties of a kind that qualify as basi¢ finanoal instruments. 88si¢ finanoal Instruments are initkglly re¢o9nised ai transaction value and subsequently measured ai their settlement value Ib.e eXpIlo of bank loans which a subsequenlly measured at arnort15ed cost using ihe etteciive interest rnethod. 2.10 Fund ac¢ounting General funds are unreslrthd fvnds which are awdilable for use al the discretion of the Tiuslees in furtherance of the general objectives of the Charity and which have noi been designated for other purposes. Designated funds cornprise unreslricted lund5 that have been sel aside by the Trustees for parti¢ular purposes. The aim and use of each designated lund is Set out sn the notes to the financial statements. Reslncfed funds are funds which are to be used in accordance wth specific restriciions irnposed by donors or which have been raised by the Charty for particular purposes. The costs of raising ancl adminislering SLtch funds are Chatged agaiasl the specific fund. Inve51rnenl income. 9ain$ and losses are allated to the appropriate fund. Page 10
BRITISH SOCIETY OF ENDOVASCULAR THEWY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2026 Income from donations and lègacits Restrf¢tefl fund$ 2026 Totsl funds 2026 CLEVAR income 34.175 34.175 R8stricl&d funds 2025 Total funds 2025 CLEVAR Inrne 35,988 35.988 Income from other trading activitie5 Income from fundrnisin9 events Unrestricted funds 2026 Total funds 2026 Annual meeting gistratrt Sponsorships 43.997 265.000 43,997 265,000 308.997 308,997 Unreslricled funtls 2025 fJnds 2025 Anftual meeting registration Sponsorships 44,571 122,000 44 5", 122.090 166.571 !65 57", ?a¢e
8RITISH SOCIEfY OF ENDOVASCULAR THERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2026 Inveslm•ftt income UnYe$trictsd funds 2026 Total fvnds 2026 Investment 1CoMe 4,377 4.377 UrJmstlTded funtls Total lunGIs 2025 2025 Investment income 956 956 Other Incoming re$our¢e$ Unrestrfcted funds 2026 Tolal funds 2026 Sprin9 course income Olher incorne 15.429 1.033 1S.429 1,033 16.462 16,462 Untgsiricled lunds 2025 Total funds 2025 Spring course sncome Olher income 28.557 2.441 28,557 2,441 30,998 30,998
BRMSH SOCIETY OF ENDOVASCULAR THEWY NOTES TO THE FINANCiAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2036 Analysis of expenditure by a¢tiviti•s Activities undertaken directly 2026 Total fund5 2026 Charil8ble actiwts'es 301.950 301,9S0 Activibes und8rtaken dir8cIIy 2025 Total lunds 2025 Charitable actiwties 165.326 165,326 Analysis of direct costs Total funds 2026 Activities 2026 Annual meelTng cosls Sundry expenses Travel and subsislence Spnng course expenditure Accountancy fees Consuttancy fees 8allk charges Joslage. printing stalM)ftery Prizes and bursaries Fellowship Purnp priming award expenditure Globalsiar expendrture 128.688 2.088 3.741 50.016 1.882 33.245 184 128,688 2.088 3,741 50.016 1,882 33,245 184 1,372 600 1,372 600 60,000 20.000 134 20.000 301.950 301,950 ?aae"3
aRmsH SOCIETY OF ENDOVASCULAR THERAPY NOYES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2026 Analysls of txpèndituwB by zctivities Icontinuedl AnalysFS of direct ¢osts Icontinu•dl Tolal funds 2025 Acbvibes 2025 Annual rneeting cosls Sundry expenses Travel and subsistence Spring course expenditure Accountancy fees Consultancy fees 8ank charges Postage. printing and siatK)nery Pnzes and bursaries Felli)wship Pump priming award expendilu Globa151ar expenditure 94.402 1.736 1.752 15,996 94.402 1. 736 1, 752 15.996 li 1,840 26.883 165 1.840 26.883 165 1.177 600 10.000 10,000 775 1.177 600 10.000 10.000 7T5 165,326 165.326 Trustees. remuneratson and expense5 During the year. no Trustees reNe any remuneralTon or other benefits 12025- £NIU. During the year ended 31 January 2026. travel expenses lotalling E1.958.99 were reirnbursed lo the trustess. D8btor5 2026 2025 Due within ont year Prepayments and accrued irtome 81,360 81.360 10. Creditors". Amounts falling duo within one year 2026 2025 Accruals and deferred income 12.104 7.680
BRlnSH SOCIETY OF ENDOVASCULAR THERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2026 f1. Ststement of fund5 Stalem8nt of funds- current year Balance 3t I February 2075 Balance at Transfers 31 January inlout 2026 Incorrte Expenditure Unrestricted funds Designatèd funds Contingency fijnd 300.000 300,000 General funds General Funds- all funds S08.718 329.836 1301.9501 1265,8Z51 270,779 Totsl Unrestricted fund$ $08.718 329.836 1301,9SOI 34,175 S70,779 Rtstrictrd fvnds 8SET CLEVAR 34.175 134.1751 Total of fvnds 508.718 364.011 13Q1.9501 570,779 Stalement ol fvnl$- prioryear 8alan¢e at l February 2024 Balance al 31 January 2025 Translers in¥oul I10m* Expendrture Unrestrictsd funds General Funds- all lunds 374. 100 198.525 (164,5511 100.644 Restricted fund$ Bs CLEVAR Globalstar 17,736 47.695 35,S188 (53, 724) (46,920) 1775J 65,431 35.988 r175} (100,644) Totsl of ftsnd$ 439537 234.573 165.3261 508 718 Pzce'i
8RITISH SOCIETY OF ENDOVASCULAR THERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2026 12. Analysis of net assèts bètween funds Analysis of net assets betweèn funds - current year Unrestricted fund$ 2026 Total fund$ 2026 Current a5set5 Creditors due wthin one year 582.883 112.1041 S82,883 112,1041 Total 570.779 570.779 Analysi$ of net a$$ets between funds- prior year Unr8Stnct8d funds 2025 Total unds 2025 Current assets Credrtors due within one year 510.398 (1,68Ql 510,398 11,6801 Totsl 508.718 508. 718 13. Related party transactions The Charity has not enlered into any related paty tranSalon duFing the year. nor are there any outstanding balancès owing behveen relaied parties and the Charity at 31 January 2026. Page 16